Researchers planning injection studies should recognise that mechanism and route are decoupled in the current evidence base
Long-term benefits develop over 46 weeks of consistent use
University of Pennsylvania
Iwilfin, an orally available inhibitor of ornithine decarboxylase, was approved based on the results of a single-arm study of children with HRNB who were initially treated with standard regimens, including immunotherapy
RNA-seq analysis revealed that DEGs between 0 mg/kg and 2 mg/kg anwuligan-treated mice were significantly enriched in several key pathways, including metabolic pathways, protein digestion and absorption, retinol metabolism, MAPK signaling pathway, PI3KAkt signaling pathway, Wnt signaling pathway, PPAR signaling pathway, BMP signaling pathway, and TGF-beta signaling pathway